4517-91-3

Basic information

• Product Name: 6-bromo-N-(4-ethoxyphenyl)-2-oxo-2H-chromene-3-carboxamide
• Synonyms: 6-bromo-N-(4-ethoxyphenyl)-2-oxo-2H-chromene-3-carboxamide
• CAS NO: 4517-91-3
• Molecular Formula: C₁₈H₁₄BrNO₄
• Molecular Weight: 388.21206
• Mol File: 4517-91-3.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-bromo-N-(4-ethoxyphenyl)-2-oxo-2H-chromene-3-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-N-(4-ethoxyphenyl)-2-oxo-2H-chromene-3-carboxamide(4517-91-3)
• EPA Substance Registry System: 6-bromo-N-(4-ethoxyphenyl)-2-oxo-2H-chromene-3-carboxamide(4517-91-3)

Safety Data

• Hazardous Substances Data: 4517-91-3(Hazardous Substances Data)

Upstream product

• 2199-94-2 6-bromo-2-oxo-2H-1-benzopyran-3-carboxylic acid chloride 
• 156-43-4 4-Ethoxyaniline 
• 51838-07-4 2-cyano-N-(4-ethoxyphenyl)acetamide 
• 1761-61-1 5-bromosalicyclaldehyde 

Relevant articles and documents

Novel hydrazide-hydrazone and amide substituted coumarin derivatives: Synthesis, cytotoxicity screening, microarray, radiolabeling and in vivo pharmacokinetic studies

The current work presents the synthesis and biological evaluation of new series of coumarin hydrazide-hydrazone derivatives that showed in vitro broad spectrum antitumor activities against resistant pancreatic carcinoma (Panc-1), hepatocellular carcinoma (HepG2) and leukemia (CCRF) cell lines using doxorubicin as reference standard. Bromocoumarin hydrazide-hydrazone derivative (BCHHD) 11b showed excellent anticancer activity against all tested cancer cell lines. Enzyme assays showed that BCHHD 11b induced apoptosis due to activation of caspases 3/7. Moreover, 11b inhibited GST and CYP3A4 in a dose dependent manner and the induced cell death could be attributed to metabolic inhibition. Moreover, 11b microarray analysis showed significant up- and down-regulation of many genes in the treated cells related to apoptosis, cell cycle, tumor growth and suppressor genes. All of the above presents BCHHD 11b as a potent anticancer agent able to overcome drug resistance. In addition, compound 11b was able to serve as a chemical carrier for 99mTc and the in vivo biodistribution study of 99mTc-11b complex revealed a remarkable targeting ability of 99mTc into solid tumor showing that 99mTc-11b might be used as a promising radiopharmaceutical imaging agent for cancer.